

Human IL-23A&IL-12B Heterodimer Protein; His

Tag

Product Information


| Product Name | Human IL-23A&IL-12B Heterodimer Protein; His Tag |
|-----------------|-------------------------------------------------------------------------------------------------------------------|
| Storage temp. | Store at \leq -70°C, stable for 6 months after receipt. |
| | Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| | |
| Catalog# / Size | GM-87924RP-100 / 100 μg |
| | GM-87924RP-1000 / 1 mg |

Protein Information

| Alternative Names | IL-23 alpha & IL-12 beta Heterodimer |
|--------------------|---------------------------------------------------------------------------------------|
| Source | Human IL-23A&IL-12B Heterodimer Protein; His Tag (GM-87924RP) is |
| | expressed from human 293 cells (HEK-293). It contains AA(IL-23A) Arg 20 - |
| | Pro 189 (Accession # Q9NPF7-1) and AA(IL-12B) Ile 23 - Ser 328 (Accession # |
| | P29460-1). |
| | This protein carries a His tag at the C-terminus of IL-12B. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/µg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 18.7 KDa (IL-23A) and 34.4 KDa (IL-12B) |
| Formulation | Supplied as a 0.2 µm filtered solution of PBS, pH7.4. |
| Description | IL-23 is a heterodimeric cytokine made of IL-23 alpha (p19) and IL-12 beta (p40) |
| | subunits. While p40 is shared with IL-12, p19 is unique to IL-23. It binds to its |
| | receptor complex (IL-23R and IL-12R β 1) to regulate Th17 cells, promoting the |
| | release of pro-inflammatory cytokines like IL-17 and IL-22, driving immune |
| | inflammation. |
| | IL-23 plays a significant role in many inflammatory and autoimmune diseases, |
| | such as psoriasis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Due |
| | to its regulation of Th17 cells and inflammatory responses, IL-23 has become an |
| | important therapeutic target. Drugs that specifically block p19 (e.g., guselkumab) |
| | have been used to treat various inflammatory diseases. Additionally, p40- |
| | targeting drugs (e.g., ustekinumab) can inhibit the functions of both IL-12 and IL- |
| | 23, thereby alleviating disease progression. |



SDS-PAGE




On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA

Bioactivity-ELISA


0.5 µg Human IL-23 alpha&IL-12 beta Heterodimer Protein; His Tag of per well




Human IL-23A&IL-12B Heterodimer Protein; His Tag (Catalog # GM-87924RP) was immobilized at 5 μ g/ml (100 μ L/well). Increasing concentrations of Anti-IL-12/23(p40) hIgG1 antibody(Ustekinumab) (Catalog # GM-46333AB) were added.




Bioactivity-ELISA





Human IL-23A&IL-12B Heterodimer Protein; His Tag (Catalog # GM-87924RP) was immobilized at 2 μg/ml (100 μL/well) on Anti-His mIgG2a Antibody (Catalog # GM-59493AB) (0.6 μg/well) precoated. Increasing concentrations of Human IL-23R Protein; hFc Tag (Catalog # GM-87925RP) were added.

Bioactivity CELL BASE



Human IL-23A&IL-12B Heterodimer Protein; His Tag (Catalog # GM-87924RP) was added into H_IL-23 Reporter 293 Cell Line (Catalog # GM-C06722), and then IL-23/IL-23R signals were stimulated.